ArticleInternational journal of clinical and experimental pathology2017
Chemerin/chemR23 association with endothelial-mesenchymal transition in diabetic nephropathy.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Adipokine networks in diabetic kidney disease: mechanistic insights and therapeutic implications.Lipids in health and disease · 2026Review
- SPM Receptor Expression and Localization in Irradiated Salivary Glands.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Article
- Reversal of Epithelial-Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids.Cancers · 2019Review
- Increased Circulating Chemerin in Relation to Chronic Microvascular Complications in Patients with Type 2 Diabetes.International journal of endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was aimed to analyze the association of chemerin/chemR23 with endothelial-mesenchymal transition (EndMT) in the kidney of rats during the progression of diabetic nephropathy (DN). Eighty male Sprague-Dawley rats were randomly distributed to age-matched control and diabetic nephropathy model groups. Diabetes was induced by intraperitoneal injection of streptozotocin (STZ). Morphological changes in the renal tissues were observed after periodic acid-Schiff staining. Chemerin and chemR23 expression was determined by immunohistochemistry. Co-expression of α-smooth muscle actin (α-SMA) and CD31 was determined by immunofluorescence double-labeling. Expression of all these markers was analyzed by Western blotting. Expression of chemerin, chemR23, and transforming growth factor-β1 (TGF-β1) genes at mRNA level was determined by qRT-PCR. Mild glomerular hypertrophy was observed at 4 weeks and mild glomerular basement membrane thickening and mesangial matrix proliferation at 12 weeks. Immunohistochemistry showed much higher levels of chemerin and chemR23 in diabetic rats compared with the control group. Expression of chemerin, chemR23, and α-SMA proteins increased with disease progression, while CD31 protein expression decreased. Expression of chemerin, chemR23, and TGF-β1 mRNAs also increased. α-SMA and CD31 co-expression increased with disease progression from 4 weeks. Spearman correlation analysis showed that chemerin mRNA levels correlated positively with Chem R23, TGF-β1, α-SMA expression, and CD31 and α-SMA double-positive cell numbers, but negatively with CD31 protein expression. In conclusion, chemerin expression correlates with EndMT in DN model rats.
Indexed as
Identifiers
31966583PMC6965245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.